72 citations
,
December 1983 in “Journal of Investigative Dermatology” Minoxidil helps hair cells live longer and grow longer.
63 citations
,
April 2003 in “Journal of The European Academy of Dermatology and Venereology” This study found that minoxidil topical solution was associated with a dose-related occurrence of hypertrichosis, especially facial hair, in women treated for androgenetic alopecia.
40 citations
,
May 1987 in “The Lancet” Minoxidil helps some bald men, but most lose hair again when stopping.
31 citations
,
August 1975 in “Journal of Pharmaceutical Sciences” This study found that different species metabolized minoxidil into various products, with monkeys and humans showing similar profiles primarily excreting a glucuronide conjugate, while rats and dogs showed distinct differences.
26 citations
,
March 1987 in “Journal of the American Academy of Dermatology” This study suggests that topical minoxidil may aid hair regrowth in alopecia areata through synergistic effects on follicular epithelium and lymphocyte-mediated immunological responses, alongside its vasodilatory properties.
23 citations
,
March 2021 in “Gels” This study found that minoxidil solubilized in gelatin-containing microemulsions resulted in over 5% of the drug remaining in porcine skin, significantly more than the reference gel.
17 citations
,
October 2013 in “F1000Research” This case report details a 2-year-old boy who developed generalized hypertrichosis after using 5% minoxidil foam for alopecia areata, highlighting the importance of caution and proper administration instructions for young children.
16 citations
,
May 2020 in “Frontiers in pharmacology” This study found that minoxidil stimulates the Kir6.2/SUR2 potassium channel, leading to tumor growth arrest in an ovarian cancer xenograft model by disrupting mitochondrial function and inducing cell death.
16 citations
,
January 2018 in “International Journal of Trichology” In this study, minoxidil significantly downregulated interleukin-1 alpha expression in human keratinocyte cells, suggesting an anti-inflammatory effect that may be a mechanism of action in treating alopecia.
12 citations
,
May 1988 in “Journal of the American Academy of Dermatology” Both 2% minoxidil gel and solution effectively increase hair growth in men with early baldness.
11 citations
,
January 1980 in “Southern Medical Journal” This study found that minoxidil effectively manages various types of severe hypertension but can cause side effects such as sodium retention and tachycardia.
9 citations
,
November 2016 in “Archives of Plastic Surgery” In this study, researchers found that a mixture of Saccharina japonica and Undaria pinnatifida (L-U mixture) promoted hair growth in mice comparably to 3% minoxidil. The L-U mixture stimulated hair growth-promoting genes and suppressed hair loss-related genes, suggesting its potential for hair loss treatments.
8 citations
,
January 2011 in “Collection of Czechoslovak Chemical Communications” This study developed and validated a sensitive method using adsorptive cathodic stripping voltammetry to directly determine minoxidil in topical solutions, shampoos, and creams, achieving high recovery rates and precision.
7 citations
,
August 2024 in “JAAD reviews.” This review reports that low-dose oral minoxidil can cause hypertrichosis due to increased systemic absorption, and highlights the importance of patient-centered care to manage the psychosocial impacts of this side effect effectively.
5 citations
,
April 2025 in “Journal of the American Academy of Dermatology” This source provides an overview of expert practices for using topical and low-dose oral minoxidil in treating hair loss, highlighting how dermatologists apply existing literature to ensure safe and effective treatment.
4 citations
,
July 1987 in “Dermatologic Clinics” 3 citations
,
January 2002 in “Actas Dermo-Sifiliográficas” In this case report, a 23-year-old woman developed localized trichorrhexis nodosa after compulsively applying 3% minoxidil to her scalp for two months.
2 citations
,
June 2025 in “Journal of the American Academy of Dermatology” Low-dose oral minoxidil can cause dizziness in women without lowering blood pressure, so careful monitoring is needed.
2 citations
,
October 2020 in “The Journal of clinical and aesthetic dermatology” In this randomized controlled study, the researchers found that an herbal extract combination showed similar efficacy to 3% minoxidil solution in treating androgenetic alopecia over 24 weeks, with no significant safety concerns, suggesting it might be a viable alternative treatment.
2 citations
,
January 2016 in “Journal of in silico & in vitro pharmacology” This study found that coencapsulating Minoxidil and Rosemary essential oil in liposomes increased Minoxidil's encapsulation efficacy, while Rosemary oil's entrapment was not significantly affected.
2 citations
,
March 2009 in “Journal of Clinical Dermatology” This study found that topical 5% minoxidil solution is effective and well tolerated for promoting hair growth in Korean men with androgenetic alopecia over 24 weeks.
1 citations
,
July 2024 in “JAAD International” This article discusses the off-label use of low-dose oral minoxidil for alopecia and reports no new clinical findings, noting its presumed mechanism is enhancing hair follicle microcirculation with minimal blood pressure effects.
1 citations
,
July 2023 in “International Journal of Biological Macromolecules” In this study, researchers developed a composite paste system using minoxidil-loaded nanoparticles and valproic acid, enhanced by roller-microneedles, which significantly stimulated hair regeneration and perifollicular vascularization in an androgenetic alopecia mouse model, reducing side effects compared to traditional treatments.
1 citations
,
March 2015 in “Oriental Journal of Chemistry/Oriental journal of chemistry” This study developed and validated a precise RP-HPLC method for simultaneously estimating minoxidil and aminexil in pharmaceutical formulations with good accuracy and specificity.
June 2026 in “Current Issues in Molecular Biology” In this study, a botanical extract and minoxidil showed similar effects in vitro by reducing pro-inflammatory cytokines and 5α-reductase expression while increasing growth factors VEGF and KGF in human keratinocyte cells, suggesting potential for further in vivo research.
May 2026 in “Journal of the American Academy of Dermatology” In this study, sublingual minoxidil was found to be a safe and effective treatment for increasing hair growth in transgender individuals with mild androgenetic alopecia who are undergoing full-dose testosterone therapy.
February 2026 in “Journal of Clinical Medicine” In this narrative review, researchers found preliminary evidence suggesting that minoxidil, both topical and oral, may enhance nail growth and improve nail strength and appearance, though more extensive studies are needed to confirm its efficacy and safety for this off-label use.
February 2026 in “Journal of the American Academy of Dermatology” In this retrospective study, researchers found that while combination therapy of spironolactone and oral minoxidil for female alopecia commonly led to mild outpatient-manageable side effects, starting both medications simultaneously reduced hypertrichosis risk, but taking multiple blood pressure medications increased hypotensive symptoms.
January 2026 in “Microchemical Journal” In this study, researchers developed an electrochemical method using gold nanostructures on a glassy carbon electrode to detect minoxidil levels in hair lotions, and found it effectively quantified minoxidil in commercial products, revealing discrepancies in their labeled versus actual concentrations.
January 2026 in “International Journal of Applied Pharmaceutics” This study developed a novel LC-ESI-MS/MS method to quantify Minoxidil in pharmaceutical forms, finding it precise, accurate, and robust. It withstands excipient and degradant interference, although Minoxidil degrades under some stress conditions but remains stable thermally.